News

01/10/2017 - Privo Technologies receives the 2016 National Tibbetts Award.

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated "We are proud to recognize your company’s outstanding work that has contributed so greatly to the success of the SBIR program." Privo would like to congratulate it's team for their hard work and dedication to the company. On January 10, 2017, Privo's CEO and Founder, Dr. Manijeh Goldberg, received the honor at the White House during a special awards ceremony. News Article

 

12/10/2015 - Privo Technologies opens new lab facility in Peabody, Ma.

Privo Technologies expands to a new 3000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place, Suite 6B in Peabody, Massachusetts, the new facility consists of two seperate research labs that will be used in it's continued pursuit of excellence in the field of cancer research. Privo's new location provides office space and conference rooms to accommodate the company's continued growth moving forward.

 

12/10/2016 - Privo Technologies receives 2015 TechConnect Innovation Award

Privo Technologies received the "2015 National Innovation Award" from the TechConnect World Innovation Conference. Privo's ChemoThin Wafer project was rated in the top 5% of all award applicants. News Article

 

09/13/2016 - Privo recieves Commercialization Award from the National Cancer Institute.

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston, and would like to thank the National Cancer Institute for funding Privo’s inclusion as part of this conference.

 

11/03/2015 - Privo recieves Orphan Designation from the Food and Drug Administration.

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Reciept of this designation entitles Privo's current and future oral cancer treatments to additional patent protection, 7 years of drug exclusivity, and tax credits equal to 50% of research and development costs. Orphan Designation will enable Privo to accelerate the drug development timeline for oral cancer treatment.

 

2012 and 2013 - Our Oral Cancer treatment receives MIT's Innovation Award two years in a row.

The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the company’s drug development activities. We are proud to receive these very competitive awards and honored to be amongst some of the best innovations coming out of Massachusetts Institute of Technology (MIT). 2012 Grant Announcement 2013 Grant Announcement

 

Boston's WomenPreneurs to Watch

The harder I network, the luckier I get
 

Privo's CEO speaks at IDEASTREAM, MIT Deshpande Center Symposium 2014

Tougher on Cancer, Easier on the Patient
 

Privo's CEO speaks at IDEASTREAM, MIT Deshpande Center Symposium 2013

Buccal Delivery of Chemotherapy to treat Oral Cancer
 

From night-vision cameras to insulin chewing gum ...

News from MIT Sloan Fellows